Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Impax Laboratories logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Advanced Chart

Key Stats

Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IPXL Stock News Headlines

Impax Global Environmental Markets Fd;Inv
Impax Large Cap Fund Individual Investor
Now that Trump’s be inaugurated, this day will be key (mark your calendar)
Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.
Impax International Sust Econ Instl
Impax US Sustainable Economy A
Impax Global Opportunities Institutional
Impax Sustainable Allocation Inv
Impax Sustainable Allocation Instl
See More Headlines

IPXL Stock Analysis - Frequently Asked Questions

Impax Laboratories, Inc. (NASDAQ:IPXL) released its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The company's revenue for the quarter was down 9.4% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NovoCure (NVCR), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/09/2017
Today
1/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:IPXL) was last updated on 1/26/2025 by MarketBeat.com Staff
From Our Partners